AbbVie to Buy Shire for $54.8 Billion in Tax Inversion

A pharmacist removes a box of Shire Resolor 1mg prolonged film-coated tablets, produced by Shire Plc, in London.

Photographer: Simon Dawson/Bloomberg

AbbVie Inc. and Shire Plc’s $54.8 billion (32 billion pound) deal will make AbbVie the largest U.S. company to move its legal address abroad to lower its taxes as U.S. lawmakers seek ways to curb the transactions.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.